Vimovo

Vimovo is a pain reliever in the form of a tablet for oral consumption, with delayed release of esomeprazole magnesium, "a stomach acid–reducing proton pump inhibitor (PPI)"[1] and naproxen, produced by AstraZeneca.[2] Vimovo is FDA approved for use for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[3] It is intended to decrease the risk of gastric ulcers from treatment with nonsteroidal anti-inflammatory drugs.[3]

Horizon Pharma

Vimoco was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to VIMOVO".[1]

In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo.[4] According to The Atlantic, "since 2014, Horizon Pharma’s net sales have been more than $455 million".[4]

References

  1. 1 2 "Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance". Horizon Pharma, Inc. Deerfield, Illinois. November 19, 2013.(NASDAQ: HZNP)
  2. ↑ "Vimovo-Astrazeneca". felleskatalogen.no.
  3. 1 2 "VIMOVO® (naproxen and esomeprazole magnesium) Tablets". Horizon Pharma. nd. Retrieved June 20, 2017.
  4. 1 2 Allen, Marshall (June 20, 2017). "How Two Common Medications Became One $455 Million Specialty Pill". The Atlantic. Retrieved June 20, 2017. After I was prescribed a brand-name drug I didn’t need and given a coupon to cover the out-of-pocket costs, I discovered yet another reason why Americans pay too much for health care.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.